BioRestorative Therapies Inc (BRTX) has a current Price-to-Book (P/B) ratio of 4.44. Compared to its 3-year average P/B ratio of 1.54, the current P/B ratio is approximately 189.05% higher. Relative to its 5-year average P/B ratio of -0.20, the current P/B ratio is about -2298.32% higher. BioRestorative Therapies Inc (BRTX) has a Forward Free Cash Flow (FCF) yield of approximately -99.46%. Compared to its 3-year average FCF yield of -68.59%, the current FCF yield is approximately 45.01% lower. Relative to its 5-year average FCF yield of -53.17%, the current FCF yield is about 87.07% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BRTX competitors is 1.32, providing a benchmark for relative valuation. BioRestorative Therapies Inc Corp (BRTX.O) exhibits a P/S ratio of 5.48, which is 316.1% above the industry average. Given its robust revenue growth of -94.95%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BRTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BRTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BRTX currently overvalued or undervalued?

What is BioRestorative Therapies Inc (BRTX) fair value?

BRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BioRestorative Therapies Inc (BRTX) is between 0.17 to 0.23 according to relative valuation method.

How does BRTX's valuation metrics compare to the industry average?

The average P/S ratio for BRTX's competitors is 1.32, providing a benchmark for relative valuation. BioRestorative Therapies Inc Corp (BRTX) exhibits a P/S ratio of 5.48, which is 316.10% above the industry average. Given its robust revenue growth of -94.95%, this premium appears unsustainable.

What is the current P/B ratio for BioRestorative Therapies Inc (BRTX) as of Mar 03 2026?

As of Mar 03 2026, BioRestorative Therapies Inc (BRTX) has a P/B ratio of 4.44. This indicates that the market values BRTX at 4.44 times its book value.

What is the current FCF Yield for BioRestorative Therapies Inc (BRTX) as of Mar 03 2026?

As of Mar 03 2026, BioRestorative Therapies Inc (BRTX) has a FCF Yield of -99.46%. This means that for every dollar of BioRestorative Therapies Inc's market capitalization, the company generates -99.46 cents in free cash flow.

What is the current Forward P/E ratio for BioRestorative Therapies Inc (BRTX) as of Mar 03 2026?

As of Mar 03 2026, BioRestorative Therapies Inc (BRTX) has a Forward P/E ratio of -1.11. This means the market is willing to pay $-1.11 for every dollar of BioRestorative Therapies Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BioRestorative Therapies Inc (BRTX) as of Mar 03 2026?

As of Mar 03 2026, BioRestorative Therapies Inc (BRTX) has a Forward P/S ratio of 5.48. This means the market is valuing BRTX at $5.48 for every dollar of expected revenue over the next 12 months.

BRTX Valuation